340 Participants Needed

Pelacarsen for Cardiovascular Disease

(ADD-VANTAGE Trial)

Recruiting at 7 trial locations
NP
Overseen ByNovartis Pharmaceuticals
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Novartis Pharmaceuticals
Must be taking: Inclisiran
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).

Are You a Good Fit for This Trial?

This trial is for people with cardiovascular disease who have high levels of a fat-protein particle called Lp(a) and are already taking Inclisiran for high LDL cholesterol. They must have stable heart disease, stroke history, or blocked arteries and be on consistent lipid-lowering therapy and other treatments for related conditions like hypertension or diabetes.

Inclusion Criteria

I completed the initial treatment phase with inclisiran.
My Lp(a) levels are 175 nmol/L or higher.
My LDL cholesterol level is above 70 mg/dL.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either pelacarsen or placebo subcutaneous injections once monthly

6 months
6 visits (in-person)

Open-label Treatment

All participants receive pelacarsen 80 mg injection once monthly

6 months
6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 months

What Are the Treatments Tested in This Trial?

Interventions

  • Inclisiran
  • Pelacarsen
Trial Overview The study tests the effectiveness of Pelacarsen compared to a placebo in lowering Lp(a) levels among participants with established arterial plaque buildup who are also receiving Inclisiran. The goal is to see if adding Pelacarsen can further reduce cardiovascular risks.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: PelacarsenActive Control2 Interventions
Participants randomized in Pelacarsen arm, will be administered pelacarsen (TQJ230) subcutaneous injection once monthly for 12 months.
Group II: PlaceboPlacebo Group3 Interventions
Participants will be administered placebo subcutaneous injection once monthly for 6 months. After Month 6, all participants will receive pelacarsen 80 mg injection for the remaining 6 months during the open-label treatment period.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals

Lead Sponsor

Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan profile image

Dr. Vas Narasimhan

Novartis Pharmaceuticals

Chief Executive Officer since 2018

MD from Harvard Medical School

Dr. Shreeram Aradhye profile image

Dr. Shreeram Aradhye

Novartis Pharmaceuticals

Chief Medical Officer since 2021

MD

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security